红皮病型银屑病治疗的研究进展  

Advances in the treatment of erythrodermic psoriasis

作　　者：周颖[1] 沙扬 于浈[1] 王文欢 吕成志[1] Zhou Ying;Sha Yang;Yu Zhen;Wang Wenhuan;Lyu Chengzhi(Department of Psoriasis,Dalian Dermatology Hospital,Dalian 116021,Liaoning,China)

机构地区：[1]大连市皮肤病医院银屑病专科,辽宁大连116021

出　　处：《中国医学前沿杂志（电子版）》2023年第11期21-28,共8页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：红皮病型银屑病是银屑病中少见的严重亚型,临床特征为全身弥漫性红斑和鳞屑。红皮病型银屑病的治疗非常困难,既往常采用传统系统性药物治疗,但部分患者存在治疗失败、不耐受等问题。随着生物制剂的不断发展,病例报道显示,不同靶点的生物制剂在红皮病型银屑病的治疗中展现了较好的有效性和安全性。本文对红皮病型银屑病的治疗进展进行综述,旨在为临床红皮病型银屑病的治疗提供参考。Erythrodermic psoriasis(EP)is a rare severe subtype of psoriasis,which is characterized by diffuse erythema and scales.The treatment of EP is very difficult.It is usually treated with traditional systemic drugs,but some patients have problems with treatment failure and intolerance.With the development of biological agents,case reports indicate that,biological agents with different targets have shown good efficacy and safety in the treatment of EP.This article reviews the therapeutic advances in erythrodermic psoriasis with the aim of providing a reference for the clinical treatment of erythrodermic psoriasis.

关 键 词：红皮病型银屑病 生物制剂 治疗 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]